Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature

Aoki, Masato; Takaya, Hisamitsu; Otani, Tomoyuki; Murakami, Kosuke; Matsumura, Noriomi

doi:10.1007/s13691-022-00571-w

Cited by 4 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most teratocarcinosarcoma cases involved a predominant component of primitive neuroepithelial cells with a high mitotic rate, as well as prominent areas of necrosis and apoptosis 13. Although teratocarcinosarcomas have been reported in the ovaries9 14 15 and cervix,16 a teratocarcinosarcoma of uterine body origin has not been reported until now, and the concept of this disease in gynaecological tumours has not been established yet.…”

Section: Discussionmentioning

confidence: 99%

Uterine carcinosarcoma showing immature teratoid-like differentiation

Naito,

Terasaki,

Ouchi

et al. 2023

BMJ Case Rep

View full text Add to dashboard Cite

A carcinosarcoma is a rare form of cancer characterised by the presence of both carcinomatous and sarcomatous components. Here, we present our experience with an extremely rare case of an uterine carcinosarcoma with immature teratoid-like differentiation. The patient was a woman in her 60s. She was referred for the evaluation of a uterine tumour. She underwent total abdominal hysterectomy with bilateral adnexectomy and received postoperative treatment with paclitaxel and carboplatin. On microscopic examination, the tumour had a heterogeneous appearance with a combination of carcinomatous and sarcomatous elements, and teratoid features. The tumour included immature squamous epithelial cells and immature epithelial glands, and focal atypical fused glands, which are consistent with endometrioid carcinoma, were identified in the endometrium. Pathological differentiation from extrarenal Wilms’ tumour and teratocarcinosarcoma was challenging. The final pathological diagnosis was uterine carcinosarcoma with immature teratoid-like differentiation. At 14 months after the surgery, the patient has not experienced recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Uterine carcinosarcoma showing immature teratoid-like differentiation

Naito,

Terasaki,

Ouchi

et al. 2023

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Ovarian teratoid carcinosarcoma (OTC) is an even rarer type of OCS, with the addition of an immature neuroectodermal component [ 64 , 65 ]. Two case reports investigated two women with confirmed OTC [ 64 , 65 ]. A 60-year-old female was diagnosed with stage IC3 OTC and underwent radical TAH-BSO, pelvic and para-aortic lymphadenectomy, and subtotal omentectomy [ 64 ].…”

Section: Introductionmentioning

confidence: 99%

“…Two case reports investigated two women with confirmed OTC [ 64 , 65 ]. A 60-year-old female was diagnosed with stage IC3 OTC and underwent radical TAH-BSO, pelvic and para-aortic lymphadenectomy, and subtotal omentectomy [ 64 ]. Two months post-surgery, the patient experienced recurrent disease with multiple liver and bone metastases on positron emission tomography CT scan (PET-CT).…”

Section: Introductionmentioning

confidence: 99%

“…Subsequently, 2 months after completing chemotherapy, the patient experienced recurrent peritoneal dissemination. The treatment involved 6 cycles of PC combined with bevacizumab, resulting in a partial response [ 64 ]. Unfortunately, 2 weeks after completing chemotherapy, the patient died due to complications from bevacizumab.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Frontiers of Ovarian Carcinosarcoma

Ismail,

Choi,

Boussios

2023

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementOvarian carcinosarcoma (OCS), also known as a malignant mixed Müllerian tumour (MMMT), is a rare and aggressive form of cancer that accounts for less than 5% of ovarian cancers. It is characterized by high morbidity and mortality rates, with a median overall survival (OS) of less than 2 years. Several factors, including advancing age, nulliparity, reduced lactation rates, decreased use of oral contraceptive pills, genetic mutations in BRCA (breast cancer) genes, and the use of assisted reproductive technology, may increase the risk of OCS. Poor prognostic factors include an advanced stage at diagnosis, older age, lymph node metastasis, suboptimal surgical cytoreduction, the presence of heterologous features on histopathology, and increased expression of vascular endothelial growth factor (VEGF), tumour protein p53, and p53 alongside Wilms tumour 1 (WT1). The main treatment approach for OCS is cytoreductive surgery followed by platinum-based chemotherapy, although immunotherapy is showing promise. Homologous recombination deficiency (HRD) testing may enhance outcomes by enabling personalized immunotherapy and targeted therapies for specific patient groups, thereby reducing unnecessary side effects and healthcare costs. However, there is currently a lack of standardised treatment regimens for OCS patients, with most studies consisting of case reports and a shortage of suitable comparator groups. This article aims to provide clinicians with information on the epidemiology, risk factors, prognostic factors, and latest therapeutic advancements in OCS.

show abstract

Amlodipine/bevacizumab

2022

Reactions Weekly

View full text Add to dashboard Cite

Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature

Cited by 4 publications

References 16 publications

Uterine carcinosarcoma showing immature teratoid-like differentiation

Uterine carcinosarcoma showing immature teratoid-like differentiation

Frontiers of Ovarian Carcinosarcoma

Amlodipine/bevacizumab

Contact Info

Product

Resources

About